GlassScriptPhysician profile
Lauren Batchelor
NPI 1043059090
$1,647.32
in general payments reported to CMS, 2019-2025
18 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $264 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.32 | 2024-2025 | |
| Corcept Therapeutics | $155.18 | 2025 | Korlym |
| Lilly USA, LLC | $146.00 | 2024 | Mounjaro, Jardiance, Zepbound |
| Madrigal Pharmaceuticals | $141.12 | 2025 | Rezdiffra |
| Novo Nordisk INC | $140.14 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $125.65 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $85.25 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $64.46 | 2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $45.97 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $28.89 | 2025 | Trelegy Ellipta |
| Mannkind Corporation | $26.21 | 2025 | |
| Intra-Sana Laboratories | $20.84 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amgen INC. | $20.13 | 2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.83 | 2024 | Xifaxan |
| Pfizer INC. | $19.53 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Watermark Medical, INC. | $14.29 | 2024 | |
| Almatica Pharma LLC | $14.29 | 2025 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.22 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Batchelor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.